News

The average Wall Street analyst following Editas Medicine (NASDAQ: EDIT) thinks the gene therapy stock can reach $3.25 per share in the next year. From recent prices, this implies a gain of ...
U.S. stock futures moved in different directions on Thursday, with enthusiasm for a potential U.S.-EU trade agreement ...